Skip to main content
Kesimpta

Please select your country (language)

Austria (Deutsch)

Belgium (Nederlands)

Denmark (Dansk)

France (Français)

Iceland (Islenska)

Lithuania (Lietuvių kalba)

Malta (Malti)

Portugal (Português)

Spain (Español)

Bulgaria (Български)

Croatia (Hrvatski)

Estonia (Eesti keel)

Germany (Deutsch)

Ireland (English)

Luxembourg (Français)

The Netherlands (Nederlands)

Romania (Română)

Sweden (Svenska)

Belgium (Français)

Cyprus (Ελληνικά)

Finland (suomi)

Greece (Ελληνικά)

Italy (Italiano)

Luxembourg (German)

Norway (Norsk)

Slovakia (Slovenčina)

UK-Northern Ireland (English)
 

Belgium (Deutsch)

Czech Republic (Česky)

Finland (Svenska)

Hungary (Magyar)

Latvia (Latviešu valoda)

Malta (English)

Poland (Polski)

Slovenia (slovenščina)

Finland-Finnish
  • Käyttöehdot
  • Evästekäytäntö
  • Evästeasetukset
© 2025 Novartis FI2112224852. huhtikuuta 2021

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Please refer to the Package Leaflet for more information.